Oncostatin M Induces IFITM1 Expression to Inhibit Hepatitis B Virus Replication Via JAK-STAT Signaling

Revill, 2019, A global scientific strategy to cure hepatitis B, Lancet Gastroenterol Hepatol, 4, 545, 10.1016/S2468-1253(19)30119-0

Fung, 2022, Getting to HBV cure: the promising paths forward, Hepatology, 76, 233, 10.1002/hep.32314

Martinez, 2021, Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections, J Hepatol, 75, 706, 10.1016/j.jhep.2021.05.013

Schuch, 2019, Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load, Gut, 68, 905, 10.1136/gutjnl-2018-316641

Lebosse, 2017, Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B, J Hepatol, 66, 897, 10.1016/j.jhep.2016.12.024

Soriano, 2018, Hepatitis B gene therapy coming to age, AIDS Rev, 20, 125

Niu, 2018, Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism, J Hepatol, 68, 922, 10.1016/j.jhep.2017.12.007

Wang, 2021, Restoration of HBV-specific CD8(+) T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-alpha therapy, Signal Transduct Target Ther, 6, 376, 10.1038/s41392-021-00776-0

Rose-John, 2018, Interleukin-6 family cytokines, Cold Spring Harb Perspect Biol, 10, a028415, 10.1101/cshperspect.a028415

Hosel, 2009, Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection, Hepatology, 50, 1773, 10.1002/hep.23226

Larrea, 2014, Characterization of the CD40L/oncostatin M/oncostatin M receptor axis as an antiviral and immunostimulatory system disrupted in chronic HCV infection, J Hepatol, 60, 482, 10.1016/j.jhep.2013.10.016

Carneros, 2019, Cardiotrophin-1 is an anti-inflammatory cytokine and promotes IL-4-induced M2 macrophage polarization, FASEB J, 33, 7578, 10.1096/fj.201801563R

Palumbo, 2015, IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome, PLoS One, 10

Larrea, 2014, Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes, Gut, 63, 665, 10.1136/gutjnl-2012-304377

Giraldez, 2021, New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology, Nat Rev Gastroenterol Hepatol, 18, 787, 10.1038/s41575-021-00473-x

Tseng, 2022, The predictive role of hepatitis B biomarkers on HBV reactivation following direct-acting antiviral therapy in HBV/HCV coinfected patients, Viruses, 14, 1812, 10.3390/v14081812

Tan, 2018, When hepatitis B virus meets interferons, Front Microbiol, 9, 1611, 10.3389/fmicb.2018.01611

Li, 2019, Human hepatitis B virus core protein inhibits IFNalpha-induced IFITM1 expression by interacting with BAF200, Viruses, 11, 427, 10.3390/v11050427

Wong, 2022, How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?, J Hepatol, 76, 1249, 10.1016/j.jhep.2021.11.024

Luo, 2016, Hepatic oncostatin M receptor beta regulates obesity-induced steatosis and insulin resistance, Am J Pathol, 186, 1278, 10.1016/j.ajpath.2015.12.028

Nakamura, 2004, Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice, Hepatology, 39, 635, 10.1002/hep.20086

Kurash, 2004, Induction and regulation of acute phase proteins in transdifferentiated hepatocytes, Exp Cell Res, 292, 342, 10.1016/j.yexcr.2003.09.002

Guerriero, 2009, Narrative-based computational modelling of the Gp130/JAK/STAT signalling pathway, BMC Syst Biol, 3, 40, 10.1186/1752-0509-3-40

de Souza, 2022, Stimulation of osteoclast formation by oncostatin M and the role of WNT16 as a negative feedback regulator, Int J Mol Sci, 23, 3287, 10.3390/ijms23063287

Hermanns, 2015, Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology, Cytokine Growth Factor Rev, 26, 545, 10.1016/j.cytogfr.2015.07.006

You, 2022, Regulation of pattern-recognition receptor signaling by HBX during hepatitis B virus infection, Front Immunol, 13, 10.3389/fimmu.2022.829923

Mesev, 2019, Decoding type I and III interferon signalling during viral infection, Nat Microbiol, 4, 914, 10.1038/s41564-019-0421-x

Tsuno, 2009, IRF9 is a key factor for eliciting the antiproliferative activity of IFN-alpha, J Immunother, 32, 803

Winkler, 2019, Analysis of IFITM-IFITM interactions by a flow cytometry-based FRET assay, Int J Mol Sci, 20, 3859, 10.3390/ijms20163859

Song, 2022, Differential transcriptomics analysis of IPEC-J2 cells single or coinfected with porcine epidemic diarrhea virus and transmissible gastroenteritis virus, Front Immunol, 13

Rajabi, 2018, MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells, Oncogene, 37, 2079, 10.1038/s41388-017-0096-9

Salerno, 2020, Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription, Gut, 69, 2016, 10.1136/gutjnl-2019-319637

Xun, 2021, Taurocholic acid inhibits the response to interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8(+) T and NK cell function, Cell Mol Immunol, 18, 461, 10.1038/s41423-020-00601-8

Lin, 2017, A critical role of transcription factor YY1 in rheumatoid arthritis by regulation of interleukin-6, J Autoimmun, 77, 67, 10.1016/j.jaut.2016.10.008